# Tirzepatide Research: Mechanism, Clinical Trials, and Comparative Evidence

> Tirzepatide's dual GIP/GLP-1 mechanism, SURMOUNT and SURPASS trial outcomes, comparative data versus semaglutide, and insulin resistance findings — summarized from the peer-reviewed literature.

## Tirzepatide Mechanism of Action

Tirzepatide simultaneously agonizes two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) [1]. It displays approximately 5-fold higher affinity at the GIPR than at the GLP-1R, and shows biased GLP-1R signaling that favors cAMP over beta-arrestin-1 recruitment [1].

The dual engagement spans five physiological pathways: (1) glucose-dependent insulin secretion via both receptors on beta cells; (2) glucagon suppression via GLP-1R; (3) transient gastric emptying delay via GLP-1R (with tachyphylaxis); (4) central appetite suppression via POMC neurons expressing both GIP and GLP-1 receptors; (5) adipocyte lipid metabolism via GIPR, augmenting fat oxidation in caloric deficit [1, 10, 21, 22].

## How Does Tirzepatide Work?

Tirzepatide activates both GIP and GLP-1 receptors simultaneously — stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying transiently, and reducing food intake via central appetite pathways [1, 22]. The biased GLP-1R signaling (cAMP-preferential over beta-arrestin) distinguishes tirzepatide from unmodified GLP-1 agonists [1].

## Tirzepatide Weight Loss Results in SURMOUNT Trials

**SURMOUNT-1 (n=2,539, 72 weeks, no diabetes):** Mean body weight reductions of 16.0%, 21.4%, and 22.5% at 5 mg, 10 mg, and 15 mg vs. 2.4% for placebo [5].

**SURMOUNT-3 (lifestyle lead-in):** Total weight loss from original baseline reached 26.6% after tirzepatide following 12-week lifestyle lead-in [6].

**SURMOUNT-4 (withdrawal design):** Participants switched to placebo regained mean 14.0% body weight over 52 weeks; 89.5% continuing tirzepatide maintained ≥80% of prior weight loss vs. 16.6% on placebo [7].

## Tirzepatide Efficacy for Glycemic Control in Diabetes Research

**SURPASS-1** (monotherapy vs. placebo, 40 weeks): HbA1c reductions of 1.87%, 1.89%, and 2.07% at 5, 10, and 15 mg; 81–86% achieved HbA1c ≤6.5% [2].

**SURPASS-2** (vs. semaglutide 1 mg, 40 weeks): Tirzepatide 15 mg reduced HbA1c by additional 0.45 percentage points vs. semaglutide; weight loss −11.2 kg vs. −5.3 kg [3].

**SURPASS-4** (vs. insulin glargine, 52 weeks): 15 mg reduced HbA1c by 2.58%; insulin glargine arm gained 1.9 kg [4].

## Tirzepatide vs Semaglutide: Comparative Trial Findings

**SURMOUNT-5** (obesity, 72 weeks, n=751): First head-to-head randomized trial in obesity. Tirzepatide produced 20.2% vs. 13.7% mean weight reduction with semaglutide 2.4 mg; 19.7% vs. 6.9% achieved ≥30% weight loss [8]. GI tolerability broadly similar [23].

## Tirzepatide and Insulin Resistance

SURPASS-2 beta-cell function substudy (n=1,879): tirzepatide improved HOMA2-B by 96.9–120.4% vs. 84.0% for semaglutide, and reduced HOMA2-IR by 15.5–24.0% vs. 5.1% for semaglutide [11].

## GIP Receptor Activity and Fat Metabolism

GIPR on adipocytes activates cAMP-mediated lipolysis via adipose triglyceride lipase upregulation and CD36 downregulation in caloric deficit [21]. This direct adipocyte GIPR effect augments fat oxidation beyond GLP-1R effects alone [21].

## Tirzepatide Effects on Blood Pressure

Systolic blood pressure reductions of 4–13 mmHg documented across SURPASS trials; 14–17.5 mmHg in participants with baseline SBP >140 mmHg. Weight loss mediated 33–57% of the SBP reduction [12].

## Weight Regain After Tirzepatide Discontinuation

SURMOUNT-4 data: approximately two-thirds of weight lost during open-label lead-in regained within one year of stopping tirzepatide [7]. Continued treatment necessary for weight maintenance.

## References

[1] Willard FS, et al. JCI Insight. 2020;5(17):e140532.
[2] Rosenstock J, et al. SURPASS-1. Lancet. 2021;398(10295):143-155.
[3] Frías JP, et al. SURPASS-2. N Engl J Med. 2021;385(6):503-515.
[4] Del Prato S, et al. SURPASS-4. Lancet. 2021;398(10313):1811-1824.
[5] Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387(3):205-216.
[6] Wadden TA, et al. SURMOUNT-3. Nature Medicine. 2023;29(11):2909-2918.
[7] Aronne LJ, et al. SURMOUNT-4. JAMA. 2024;331(1):38-48.
[8] Jastreboff AM, et al. SURMOUNT-5. N Engl J Med. 2025;393(1):26-36.
[10] Urva S, et al. Gastric emptying. Diabetes Obes Metab. 2020;22:1886-1891.
[11] Frias JP, et al. SURPASS-2 beta-cell substudy. J Clin Endocrinol Metab. 2024;109(7):1745-1753.
[12] Lingvay I, et al. SBP reduction. Cardiovasc Diabetol. 2023;22:66.
[21] Coskun T, et al. Cell Metabolism. 2024;36(7):1411-1429.
[22] Liu QK. Frontiers in Endocrinology. 2024;15:1431292.
[23] Jastreboff AM, et al. SURMOUNT-5 GI tolerability. N Engl J Med. 2025;393(1):26-36.

---

The tirzepatide clinical record — mechanism, trials, and pharmacokinetics — read from primary sources, cited numerically, and held by no clinic and no vendor.